This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Hang on a second…

This CME Activity has expired and is no longer available for credit.

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Expert Perspectives™: The Illusive Irritable Bowel Syndrome with Diarrhea-Targeting Etiology with Emerging Therapies

Expert Perspectives™: The Illusive Irritable Bowel Syndrome with Diarrhea-Targeting Etiology with Emerging Therapies

Format

Roundtable

Time to Complete

30 minutes

Released

May 20, 2016

Expires

May 20, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider




Provided by Imedex

Commercial Supporter

Supported by Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC

Program Description

Expert PerspectivesTM: The Illusive Irritable Bowel Syndrome with Diarrhea–Targeting Etiology with Emerging Therapies will provide practical guidance on the optimal clinical use of emerging agents and evolving treatment paradigms in IBS-D. This activity will highlight new therapies and how to use them in combination with other supportive therapies; diagnosing underlying etiology; and a review of therapies under investigation.

Intended Audience

This online educational activity is designed to meet the educational needs of internal medical physicians, primary care physicians, gastroenterologists, and other healthcare professionals (physician assistants, physicians-in-training, nurses, pharmacists, etc.) who are involved and/or interested in the treatment of patients with IBS-D.

Educational Objectives

Upon successful completion of the recommended education, participants will be better able to:

  • Assess the pathophysiology of IBS-D, the various etiologies that may contribute to the disease, and how current therapies target these underlying causes
  • Assess current diagnostic criteria and testing options for IBS-D
  • Evaluate the latest therapies for IBS-D, their mechanism of action, and how they should be used in clinical practice
  • Evaluate the use of combination therapy in IBS-D

Faculty

Brian E. Lacy, MD, PhD
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Baharak Moshiree, MD, MS
University of Miami Health System
Miami, FL

Nicholas J. Talley, MD, PhD, AGAF
Mayo Clinic
Rochester, MN

Faculty Disclosures:
All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Brian E. Lacy, MD, PhD: Allergan(2), Ironwood(2), Salix(2).

Baharak Moshiree, MD, MS: Focus Medical(3), Given Imaging(3), Prometheus Laboratories(3), Synergy(3).

Nicholas J. Talley, MD, PhD, AGAF: Abbott Pharmaceuticals(1), Adelphi values(2), Allergens PLC(2), GI Therapies(1,2), Janssen(1), Prometheus(1), Pfizer (at mayo Clinic)(1), Rome Foundation(1), Salix (at Mayo Clinic)(1), Yuhan(2).

Accredited Provider Disclosure

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options, clinically relevant and evidence-based recommendations, and avoid bias towards any specific commercial product and/or service.

Publishing Staff Disclosures

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following:

Chris Bolwell, Chief Operating Officer, owns shares of stock of GlaxoSmithKline.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Imedex, LLC designates this enduring educational activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hour of Category 1 credit for completing this program.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Disclosure of Unlabled Use

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your account's CME History, which you can access at any time.

Privacy Policy

Add to Queue